Clinical Trial Results
Showing:
All studies
[change]
Condition: Breast Cancer
Location: Nashville, Tennessee
25 trials found
New Search
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
RECRUITING
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
RECRUITING
Inherited CAncer REgistry
RECRUITING
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING
The PREDICT Registry:
RECRUITING
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RECRUITING
Pan Tumor Rollover Study
RECRUITING
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RECRUITING
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
RECRUITING
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RECRUITING
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
RECRUITING
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RECRUITING
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING
ATEMPT 2.0: Adjuvant T-DM1 vs TH
RECRUITING
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RECRUITING
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
RECRUITING
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
RECRUITING
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RECRUITING
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
RECRUITING
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RECRUITING
Met Non Small Cell Cancer Registry (MOMENT)
RECRUITING